

EXHIBIT B

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 60772-PCT-US		U.S. Serial No. 09/768,872				
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicant: Rina Aharoni et al.		Group Art Unit				
				Filing Date: January 23, 2001						
U.S. PATENT DOCUMENTS										
Examiner Initial		Document Number				Date	Name	Class	Subclass	Filing Date if Appropriate
		1 3 9 9 1 2 1 0				11/9/76	Shea			
		2 4 1 2 9 6 6 6				12/12/78	Wizerkaniuk			
		3 4 5 9 4 4 0 9				11/19/74	Hayashi et al.			
		4 5 9 6 5 6 0 0				10/12/99	Sato, et al.			
		5 6 0 2 4 9 8 1				2/15/00	Khankari, et al.			
		6 6 1 6 2 8 0 0				12/19/00	Dolle, et al.			
		7 6 3 6 2 1 6 1				3/26/02	Kontino, et al.			
		8 6 5 1 4 9 3 8				2/4/03	Giad, et al.			
FOREIGN PATENT DOCUMENTS										
		Document Number				Date	Country	Class	Subclass	Translation
										Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)										
	47	Aharoni, et al., "Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis", <u>Proc. Natl. Acad. Sci. USA</u> , 1997, <u>94</u> , 10821-10826								
	48	Aharoni, et al., "Cop 1 Specific Suppressor Cells Inhibit Experimental Allergic Encephalomyelitis Induced by Either Mouse Spinal Cord Homogenate or Proteolipid Protein Peptide 139-151", <u>Neurology</u> , 1997, Vol. 48, No. 3, A422								
	49	Aharoni, et al., "Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1", <u>Journal of Neuroimmunology</u> , 1998, <u>91</u> , 135-146								
	50	Asakura et al., "A unique population of circulating autoantibodies promotes central nervous system remyelination", <u>Multiple Sclerosis</u> , 1998, <u>4</u> , 217-221								
	51	Asakura et al., "Targeting of IgMk Antibodies to Oligodendrocytes Promotes CNS Remyelination", <u>The Journal of Neuroscience</u> , 1998, <u>18</u> (19), 1700-1108								
	52	Batchelor, et al., <u>Lancet</u> , 1980 <u>1</u> (8178):1107-9								
	53	Bieber, et al., "Antibody-mediated remyelination: relevance to multiple sclerosis", <u>Multiple Sclerosis</u> , 2000, <u>6</u> (2), S1-S5								
	54	Bieber, et al., "Humoral autoimmunity as a mediator of CNS repair", <u>A Trends Guide to Neurodegenerative Disease and Repair/Review</u> , 2001, <u>24</u> (11), S39-S44								
	55	Bodanszky, M., "Principles of Peptide Synthesis," Springer-Verlag, Berlin, Heidelberg, New York, Tokyo, 1984, 118-229								
	56	Bornstein, "Clinical Experience: Hopeful Prospects In Multiple Sclerosis", <u>Hospital Practice</u> , 1992, Vol. 27, No. 5, pp. 135-158								
	57	Duda, et al., "Human and Murine CD4 T Cell Reactivity to a Complex Antigen: Recognition of the Synthetic Random Polypeptide Glatiramer Acetate", <u>The Journal of Immunology</u> , 2000, <u>165</u> , 7300-7307								
EXAMINER						DATE CONSIDERED				
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>										

Applicants: Rina Aharoni et al.
 Serial No.: 09/768,872
 Filed: January 23, 2001
Exhibit A

Applicants : Rina Aharoni et al.
 Serial No. : 09/768,872
 Filed : January 23, 2001

Exhibit B

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 60772-PCT-US		U.S. Serial No. 09/768,872								
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicant: Rina Aharoni et al.		Group Art Unit								
				Filing Date: January 23, 2001										
U.S. PATENT DOCUMENTS														
Examiner Initial		Document Number						Date	Name	Class	Subclass	Filing Date if Appropriate		
	9	6	6	2	0	8	4	7	9/16/03	Konfino, et al.				
	10	6	8	0	0	2	8	5	10/5/04	Yong & Chabot				
	11	6	8	0	0	2	8	7	10/5/04	Gad, et al.				
	12	6	8	4	4	3	1	4	1/18/05	Eisenbach-Schwartz, et al.				
	13	6	9	3	9	5	3	9	9/6/05	Konfino et al.				
	14	7	0	2	2	6	6	3	4/4/06	Gilbert et al.				
FOREIGN PATENT DOCUMENTS														
		Document Number						Date	Country	Class	Subclass	Translation		
													Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
	58	Fatma, et al., <u>Swiss Med. Wkly</u> , 2003, 133:541-543												
	59	Giuseppina, et al., <u>The Journal of Clinical Investigation</u> , April 2003, Vol. 111, No. 8, 1171-80												
	60	Harrison and Hafner, "Antigen-Specific Therapy for Autoimmune Disease", <u>Current Opin. Immunol.</u> , 2000, 12(6): 704-711												
	61	Johnson, et al. "Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group", <u>Neurology</u> , 45(7), 1268 (abstract)												
	62	Kobayashi, et al., <u>Clinical Exp. Immunology</u> , 1990, June 80(3):400-3												
	63	Korezyn, et al., "Safety profile Of copolymer 1: Analysis Of Cumulative Experience In The United States And Israel", <u>J. Neurol</u> , 1996, Vol. 243 (Suppl. 1), S23-S26												
	64	Lombardi, et al., <u>J. Invest. Dermatol.</u> , 1999 July 113(1):107-10												
	65	Lovell, K. and Jones, M., "CNS Infections, Spongiform Encephalopathy and Demyelinating Diseases," Karol Marcinkowski U. Med. Sci., Dept. Pathol., Poland, last updated on 2003-04-20, <URL:http://ampat.amu.edu.pl/guzyuno/CNS_INFE.HTM>												
	66	Lymberi, et al., <u>Arch. Hellen. Med.</u> , 16(4), July-August 1999, 337-351												
	67	McGavern, et al. "Do Antibodies Stimulate Myelin Repair in Multiple Sclerosis?", <u>The Neuroscientist</u> , 1999, 5(1), 19-28												
EXAMINER								DATE CONSIDERED						
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 60772-Z-PC-T-US		U.S. Serial No. 09/768,872					
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicant: Rina Aharoni et al.		Group Art Unit					
				Filing Date: January 23, 2001							
U.S. PATENT DOCUMENTS											
Examiner Initial		Document Number				Date	Name	Class	Subclass	Filing Date if Appropriate	
	15	7	0	3	3	5	8	2	4/25/06	Yong et al.	
	16	7	0	7	4	5	8	0	7/22/06	Gad et al.	
	17	20	02	00	37	8	4	8	3/28/02	Einsenbach-Schartz et al.	
	18	20	02	00	55	4	6	6	5/9/02	Aharoni et al.	
	19	20	02	00	77	2	7	8	6/20/02	Yong et al.	
	20	20	02	01	07	3	8	8	8/8/02	Vandenbark	
	21	20	03	01	70	7	2	9	9/11/03	Klinger	
	22	20	04	00	06	0	2	2	1/8/04	Strominger et al.	
FOREIGN PATENT DOCUMENTS											
		Document Number				Date	Country	Class	Subclass	Translation	
										Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)											
	68	Merck Manual of Diagnosis and Therapy, <u>Merck Research Laboratories</u> , Whitehouse Section, N.J., 17 th Ed., 1999, 1300-1303, 1312-1317									
	69	Pavelko, et al., "Acceleration in the Rate of CNS Remyelination in Lysolecithin-Induced Demyelination", <u>The Journal of Neuroscience</u> , 1998 18 (7), 2498-2505									
	70	Pender, et al., <u>Internal Med. Journal</u> , 2002, 32: 554-563									
	71	Pharmacia Biotech Directory, 1996, pages 340-341									
	72	Physician's Desk Reference, 2000, Medical Economics Co. Inc., Montvale, NJ, 3115									
	73	Racadot, et al., "Treatment of Multiple Sclerosis With Anti-CD4 Monoclonal Antibody", <u>J. of Autoimmunity</u> , 1993, Vol. 6, pp. 771-786									
	74	Rodriguez, et al., "Immunoglobulins Reactive With Myelin Basic Protein Promote CNS Remyelination", <u>Neurology</u> , 1996, Vol. 46, pp. 538-545									
	75	Rodriguez, et al., " <u>Neurological Therapeutics</u> ", 1998, 15 (3): 245-250									
	76	Sela, M., et al., "Synthetic Approaches to Vaccines for Infectious and Autoimmune Diseases", <u>Vaccine</u> , 1992, Vol. 10, Issue 14, 991-999									
	77	Sridama, et al., <u>Arch Intern Med.</u> , 1987, 147:229-231									
	78	Teva, et al., "Copolymer-I Glatiramer Acetate Copaxone Agent for Multiple Sclerosis", <u>Drugs of the Future</u> , 1998, Vol. 23, No. 2, 213-214									
	79	Ure, et al., "Polyreactive Antibodies To Glatiramer Acetate Promote Myelin Repair In Murine Model Of Demyelinating Diseas", <u>FASEB Journal</u> , 2002, Vol. 16, pp. 1260-1262									
EXAMINER						DATE CONSIDERED					
<p><small>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small></p>											

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 60772-Z-PCT-US		U.S. Serial No. 09/768,872	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicant: Rina Aharoni et al.			
				Filing Date: January 23, 2001		Group Art Unit	

U.S. PATENT DOCUMENTS													
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate						
	23	20 05 00 19 3 2 2	1/27/05	Rodriguez et al.									
	24	20 05 01 70 0 0 4	8/4/05	Rosenberger									
	25	20 05 01 71 2 8 6	8/4/05	Konfino et al.									
	26	20 05 02 56 0 4 6	11/17/05	Gad et al.									
	27	20 06 00 52 5 8 6	3/9/06	Dolitzky									
	28	20 06 01 22 1 1 3	6/8/06	Pinchasi et al.									
	29	10 5 4 3 7 6 4	7/18/05	Aharoni et al.									
	30	10 5 4 7 4 6 3	8/30/05	Pinchasi et al.									

FOREIGN PATENT DOCUMENTS												
		Document Number	Date	Country	Class	Subclass	Translation					
							Yes	No				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
80	Vandenbark, et al., "Specificity Of T Lymphocyte Lines For Peptide Of Myelin Basic Protein", <u>The J. Of Immunology</u> , 1985, Vol. 135, pp. 229-233
81	Van Noort, et al., <u>International Review of Cytology</u> , 1996, 178: 127-205
82	Wan, et al., <u>Human Immunology</u> , 2002, Apr. 63(4):301-10
83	Warrington, et al., "Immunoglobulin-mediated CNS repair", <u>J. Allergy Clin. Immunol.</u> , 2001, S121-S125
84	Warrington, et al., "Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis", <u>Neurobiology</u> , 2000, 97(12), 6820-6825
85	Webster's II New Riverside University Dictionary, definition of "preventing", The Riverside Publishing Co., 1984, page 933
86	Weilbach, et al., "Disease Modifying Treatments For Multiple Sclerosis: What Is On The Horizon?" <u>CNS Drugs</u> , 1999, Vol. 11, No. 2, pp. 133-167
87	Wiesemann, et al., "Glatiramer Acetate (GA) induces IL-13/IL-5 secretion in naïve T cells", <u>Journal of Neuroimmunology</u> , 2001, 119, 137-144
88	Zhang, et al., "Murine Monoclonal Anti-Myelin Basic Protein (MBP) Antibodies Inhibit Proliferation And Cytotoxicity Of MBP-specific human T cell clones", <u>J. of Neuroimmunology</u> , 1989, Vol. 24, pp. 87-94
89	"About Copaxone", Internet Article URL: http://www.mswatch.com/therapy/section.aspx?SectionId=789eabf5-3a07-4dff-a7ee-0d4ad138a6d
90	URL: http://ntri.tamuk.edu/immunology/autoimmunity.html .

EXAMINER	DATE CONSIDERED
-----------------	------------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

